Clackson joins Theseus as CEO, plus Calliditas, Cerevel, VistaGen, Escient and Shoreline

Theseus Pharmaceuticals Inc. hired Tim Clackson as president and CEO to succeed Iain Dukes, the co-founder and OrbiMed venture partner who has held the CEO role on an interim basis. Dukes will become chairman of the targeted oncology play, and Clackson, who was president at CTO at tumor-selective immunotherapy company Xilio Therapeutics Inc., will join the board.

Orphan disease company  Calliditas Therapeutics AB (SSE:CALTX; NASDAQ:CALT) promoted Andrew Udell to president, North America from head of North America commercial. ...